Koers Rapid Therapeutic Science Laboratories, Inc. Other OTC
Aandelen
RTSL
US7534311052
Farmaceutische producten
Omzet 2021 | 0 0 | Omzet 2022 | - | Marktkapitalisatie | 5,82 mln. 5,36 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2021 | -2 mln. -1,84 mln. | Nettowinst (verlies) 2022 | -1 mln. -920K | EV/omzet 2021 | 93.978.853.933 x |
Nettoschuld 2021 | 1,79 mln. 1,65 mln. | Nettoschuld 2022 | 3,83 mln. 3,53 mln. | EV/omzet 2022 | - |
K/w-verhouding 2021 |
-16,6
x | K/w-verhouding 2022 |
-3,24
x | Werknemers | - |
Dividendrendement 2021 * |
-
| Dividendrendement 2022 |
-
| Vrij verhandelbaar | 75,41% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Donal Schmidt
CEO | Chief Executive Officer | 63 | 15-11-19 |
D. Watler
DFI | Director of Finance/CFO | 75 | 15-11-19 |
Sean P. Berrier
PRN | Corporate Officer/Principal | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
D. Watler
DFI | Director of Finance/CFO | 75 | 15-11-19 |
Donal Schmidt
CEO | Chief Executive Officer | 63 | 15-11-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+42,38% | 6,26 mld. | |
-15,86% | 4,49 mld. | |
+6,36% | 3,29 mld. | |
-11,28% | 3,12 mld. | |
-3,23% | 2,5 mld. | |
+45,24% | 1,94 mld. | |
-7,89% | 1,68 mld. | |
-0,98% | 1,63 mld. | |
-11,32% | 1,56 mld. |